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Many patients present with myocardial ischemic symptoms, but fail to be diagnosed of 
obstructed coronary artery disease, since the normal coronary arteries or no any 
atherosclerosis stenosis ≥ 50% at coronary angiography. Myocardial ischemia can be 
caused by either abnormalities of epicardial coronary arteries or coronary microvascular 
dysfunction (CMD). Patient with microvascular angina in the absence of coronary 
artery disease and myocardial diseases, CMD is suggested to be the unique cause of 
symptoms. The previous clinical and pathogenetic classification of CMD is based on 
presence or absence of coronary artery disease, myocardial diseases, or other traditional 
risk factors, which would obscure the importance of the disease primarily provoked by 
CMD. The role of atherosclerotic plaque rupture in epicardial coronary arteries and the
abnormality of hemorheology (especially in perimenopausal women) should be more 
stressed in the pathogenetic mechanism of CMD. The pathogenetic mechanism of 
CMD will be classified according to microvascular structure (embolization and 
stenosis), microvascular function and blood risk factors in this paper. The CMD related 
diseases including cardiac X syndrome and coronary slow flow would be better
uniformly named as microvascular angina. While little data supported therapies for 
CMD related diseases so far, the blood healthy therapy as a novel method is 
recommended to treat microvascular angina, especially in the patients with high 
hematocrit, increased blood viscosity and coronary slow flow.
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INTRODUCTION
Myocardial ischemia can be caused by abnormalities of 
epicardial coronary arteries as well as coronary 
microvascular dysfunction (CMD) [1-6]. CMD is 
defined as impaired coronary flow reserve and 
myocardial ischemia owing to structural and/or 
functional abnormalities of the microcirculation. 
Diseases related to CMD include cardiac syndrome X 
(CSX), coronary slow flow (CSF) and microvascular 
angina (MVA), in which the patients present with 
myocardial ischemic symptoms, and have either normal 
coronary arteriogram or non-obstructive (< 50% 
stenosis) coronary artery disease (CAD) [1-6]. 
Diagnosis of MVA requires an extensive workup to rule 
out other potential causes of chest pain and can be 
relatively expensive. Treatment with conventional anti-
anginal medications is often not successful, which 
results in patients being limited in their daily activities, 
seeking emergency care for their chest pain, and needing 
to take time off or abandon their work because of 
persistent symptoms. Prolonged and recurrent chest 
pain also necessitates repeated coronary arteriographies 
as well as regular outpatient visits. The lifetime cost of 
healthcare for a woman with non-obstructive chest pain 
is estimated at approximately $1 million [7, 8] which is 
often comparable with that caused by obstructive CAD. 
CMD can be classified into the following categories: in 
the absence of CAD and myocardial diseases, in the 
presence of myocardial diseases, in the presence of 
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obstructive epicardial CAD, iatrogenic dysfunction [1-
5], and after cardiac transplantation [3]. The 
pathogenetic mechanisms of CMD can be structural, 
functional or extravascular [1, 3]. In MVA, patients with 
angina attacks in the absence of CAD and myocardial 
diseases, CMD has been suggested to be the unique 
cause of symptoms [2, 3, 6]. Given the CMD as the 
pathogenetic mechanism in MVA, the role of 
atherosclerotic plaque rupture in epicardial coronary 
arteries [9], as well as the abnormality of hemorheology 
[10], especially in perimenopausal women, should have 
been stressed in the development of CMD. This article 
will focus on CXS, CFS and MVA, discuss the 
pathogenesis of CMD from microvasculature to blood, 
and introduce the blood healthy therapy as a novel 
method for treatment and prevention of MVA. 
Pathogenetic Mechanisms of CMD 
The coronary arterial system is composed of different 
compartments which including large epicardial arteries 
(500µm to 2 to 5mm in diameter), pre-arterioles (< 
500µm), arterioles (< 200µm, intramyocardial vessel) 
[1, 3], and capillaries (~7µm). The coronary 
microcirculation is the coronary arteries that are not be 
visualized at angiography (< 500µm), which are 
important in regulating blood flow to match oxygen 
demand, inflammation, coagulation, and permeability. 
The pathogenetic mechanisms of CMD will be reviewed 
and classified in microvascular structure (embolization 
and stenosis), microvascular spasm and blood risk 
factor, as shown in Table 1.  
 
Table 1. Classification of Pathogenetic Mechanisms of Coronary Microvascular Dysfunction 
 Microvascular angina Macrovascular angina 
 CSX CSF CAD 
Severity of epicardial coronary stenosis  1-49% 1-49% ≥50% 
Microvascular embolization + ++ + 
Plaque rupture + + + 
Microvascular stenosis ++ + ± 
Atherosclerotic disease burden  + ++ 
Diabetes  + + + 
Hypertension  + + + 
Micro-vasculitis +   
Microvascular spasm    
Endothelial dysfunction + + ± 
Abnormal autonomic nervous system  +   
Blood risk factors    
Blood viscosity↑ ++ + ± 
Hematocrit↑ + ± ± 
Dyslipidemia  ± ± ± 
Homocysteine↑ ± ± ± 
Lipoprotein (a)↑ ± ± ± 
Inflammatory cytokines↑ + + + 
Other factors    
Female/male  ++/± ±/++  
Perimenopause  +  + 
Current smoking   ++ + 
Emotional stress  +  ± 
Cold outside + + ± 
Oxygen-poor/enclosed environment +   
± indicates may /or may not have effect; + indicates having effect; ++ indicates having more effect. 
CSX : cardiac syndrome X, CSF: coronary slow flow, CAD: coronary artery disease. 
 
Microvascular Embolization 
Microvascular embolization is one microvascular 
structure abnormality mainly caused by either plaque 
rupture or erosion in epicardial coronary arteries. After 
atherosclerosis plaque rupture or erosion, three harmful 
consequences could be followed: (1) acute large 
thrombotic occlusion of a coronary artery presents with 
acute coronary syndrome; (2) debris released from 
necrotic core leads to distal microvascular embolization 
causing CMD; (3) microvascular embolization and 
large thrombosis forms simultaneously or successively. 
Many times after plaque rupture there is no large 
thrombosis without typical acute coronary syndrome, 
but some microvascular embolization or microvascular 
obstruction forms as the debris obstructs blood flow in 
pre-arterioles, arterioles and capillaries [11, 12]. A 
sparse distribution of myocardial ischemia or necrosis 
leads to small area or foci of myocardial infarction. It is 
sufficient to produce ECG changes and myocardial 
perfusion scintigraphic defects, but may not result in 
detectable contractile abnormalities, because of the 
normal function of the surrounding myocardial tissue. 
Similarly, the release of ischemic metabolites by the 
sparse myocardial ischemic foci into the coronary sinus 
can go undetected because of their dilution in the larger 
flow normal myocardial areas [2, 4]. Actually, in lesions 
with advanced lumen narrowing (>50% stenosis), 
histopathology almost invariably reveals 1 or more 
healed subclinical plaque ruptures. Plaque rupture is not 
only found in the narrowest coronary artery [13]. Plaque 
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rupture and its healing lead to progressive lumen 
obstruction. Plaque rupture and its healing can also lead 
to CMD and small area of new or old myocardial 
infarction. Repeat hospitalization for chest pain might 
associate with plaque rupture or erosion [9], if some 
coronary arteries were stenotic at angiography.  
Numerous studies have provided the evidence that the 
particular matter and vasoactive molecules releasing 
into the microcirculation at the time of percutaneous 
coronary intervention (PCI) and can cause CMD [1, 4, 
14]. 
Microvascular Stenosis 
Microvascular stenosis is another structural 
pathogenetic abnormality related to CMD. Studies 
reported that all patients with angina in the absence of 
obstructive CAD had some evidence of atherosclerosis 
[15]. Pathophysiological consequences of 
atherosclerosis may extend into coronary pre-arterioles 
or arterioles, where intimal atherosclerotic injury may 
relate to microvascular stenosis [4, 5], which might 
occur in hypertension, type 2 diabetes, micro-vasculitis 
(infection or rheumatoid disease), and coronary artery 
virus infection after cardiac transplantation. The 
structural abnormalities of the small intramural 
coronary arteries include medial hypertrophy, intimal 
hyperplasia, decreased luminal size and low resilience of 
arterioles, which are likely to induce CMD and 
myocardial ischemia. Additionally, the extramural 
compression of microvasculature by hypertrophic 
myocyte or myocardial edema makes arterioles luminal 
size to decrease, and affects myocardial blood flow, 
leading to CMD in hypertrophic cardiomyopathy, 
myocarditis, myocardial infarction, and no-reflow after 
PCI [15]. 
Microvascular Spasm 
Mircrovascular spasm is considered as a functional 
abnormality of microvasculature, without stenosis or 
embolization in pre-arterioles and arterioles. When focal 
inflammation occurred in coronary microvasculature, 
the abnormal nitric oxide metabolism and the 
dysregulation of inflammatory cytokines would result in 
endothelial and/or medial smooth muscle dysfunction 
or injury. Impairment in endothelium-dependent 
dilation of the coronary microvasculature occurs in the 
early stages of epicardial atherosclerosis. Adrenergic 
receptors and alterations in the expression or 
production of local vasoactive substances such as 
angiotensin II and endothelin might take an important 
role for development of microvascular spasm [4]. The 
pathogenesis of CMD may variously involve a transient 
increase in neurohumoral vasoconstrictor activity and a 
background of increased susceptibility to 
vasoconstrictor agents by the coronary microcirculation 
[2]. An increased activity of the sympathetic autonomic 
nervous system coupled with parasympathetic 
withdrawal leads to abnormal coronary microvascular 
tone. Declined protection of estrogen to endothelium 
thereby preferentially impacts peri- or postmenopausal 
women to be with microvascular spasm. 
The endothelial and/or medial smooth muscle 
dysfunction, which can involve the whole coronary tree, 
can lead to severe coronary constriction that can be 
caused by a diversity of stimuli, e.g. exercise, anxiety, and 
yet unidentified triggers [16]. In one study, one hundred 
twenty-four patients with exertional angina and 
angiographically normal coronary arteries (0-20% 
diameter reduction) underwent intracoronary 
acetylcholine test. Coronary spasm was seen in 77 
patients, 35 patients (45%) with epicardial spasm 
(≥75% diameter reduction with reproduction of the 
symptoms of the patient) and 42 patients (55%) had 
microvascular spasm (reproduction of symptoms, 
ischemic electrocardiographic changes, and no 
epicardial spasm) [16]. In another study, in 139 patients 
with angina in the absence of obstructive coronary artery 
disease, 32 patients (23%) had no coronary explanation 
for their angina, with normal endothelial function, 
normal coronary physiological assessment, and no 
myocardial bridging [17]. 
Blood Risk Factors 
The risk factors of blood are conceivably associated with 
CMD. The risk factors include elevated hematocrit 
[18], erythrocyte (~7µm in diameter) with low 
deformability, hyperlipidemia, hyperglycemia, over-
sensitive inflammatory cytokines, erythrocyte-immune 
complex after infection [19], increased plasma viscosity, 
and hypercoagulation. Specially, high level of 
fibrinogen, together with systemic or local suppression 
of fibrinolytic performance and platelet aggregation, 
leading to transient thrombosis or microvascular 
embolization that impairs the coronary blood flow or 
myocardial microcirculation, would be the risk for 
myocardial infarction [20], also play an important role 
in pathogenesis of CMD.  
The changes of erythrocyte and the cholesterol in 
erythrocytes should be specially addressed in peri- or 
postmenopausal women. Free cholesterol content of the 
erythrocyte membranes exceeds that of all other cells in 
the body, with lipid constituting 40 percent of the 
weight. By contributing to the deposition of free 
cholesterol, and enlargement of the necrotic core, the 
accumulation of erythrocyte membrane within an 
atherosclerotic plaque may represent a potent 
atherogenic stimulus, and increase the risk of plaque 
destabilization [21]. As the estrogen level declining in 
postmenopausal women, forty years’ regularity of 
menstruation (discharging about 60 ml blood each 
month) would cease abruptly. The natural way for 
releasing lipid in erythrocyte would close. That might 
affect the content and metabolism of cholesterol in 
erythrocyte, and lead to abnormality of hemorheology 
(elevated hematocrit, erythrocyte with low 
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deformability and increased blood viscosity), which 
would associate with the development of thrombosis or 
microvascular embolization, therefore, increase the risk 
of cardiovascular events as well as play the pathogenesis 
role of CMD. 
In the development of CMD, the vascular and blood 
factors can play the role independently, or interact with 
each other. Based on coronary microvascular stenosis, 
microvascular coronary spasm together with increased 
blood viscosity and slow blood flow would impair 
microcirculation more frequently. If so, recurrent focal 
myocardial ischemia and even microvascular 
embolization formation might occur, leading to 
cardiomyocyte apoptosis and necrosis, microvascular 
myocardial infarction and localizer of replacement 
fibrosis. Other factors contributing to CMD include 
female, positive family history as genetic background 
and lifestyle such as smoking, alcohol drinking, 
postprandial and even cold weather.  
CMD related Diseases 
Recurrent ischemic chest pain and the risk of myocardial 
infarction and heart failure were still very high even after 
successful PCI in many patients with CAD and CMD 
[2-4]. Some patients with diabetes hospitalized for heart 
failure as the onset symptoms, since the main 
pathogenesis of diabetes was CMD at the early stage of 
disease. Other diseases, such as hypertrophic 
cardiomyopathy, dilated cardiomyopathy, aortic 
stenosis, myocarditis, Anderson-Fabry’s disease and 
amyloidosis, are associated with CMD in the 
pathogenesis. However, this review will focus on CSX, 
CSF and MVA, in which the patients present with 
myocardial ischemic symptoms, but fail to be diagnosed 
of obstructed CAD, since the normal coronary arteries 
or no any atherosclerosis stenosis ≥ 50% at coronary 
angiography [3-5]. 
CSX 
Harvey Kemp in 1973 named CSX, which could be 
defined broadly as angina-like chest discomfort with 
normal epicardial coronary arteries on angiography. A 
proposed more strict definition of CSX entails the 
following criteria: (1)exercise-induced, angina-like 
chest discomfort; (2) ST-segment depression during 
angina; (3) normal epicardial coronary arteries at 
angiography; (4) no spontaneous or inducible 
epicardial coronary artery spasm upon ergonovine or 
acetylcholine provocation; (5) absence of cardiac or 
systemic disease associated with microvascular 
dysfunction such as hypertrophic cardiomyopathy or 
diabetes.7 For many years, it was thought that CSX had 
a benign prognosis, however, recent evidence has 
challenged the assumption. Five-year annualized event 
rates for cardiovascular events (myocardial infarction, 
stroke, and hospitalization for heart failure) were 16.0% 
in symptomatic women with nonobstructive CAD 
(stenosis 1% - 49%), 7.9% in symptomatic women with 
normal coronary arteries (0% stenosis), and 2.4% in 
asymptomatic women [22]. 
In patients with recurrent chest pain, the absence of any 
angiographic lesion greater than 50% in any coronary 
vessel is the primary exclusion criteria for the diagnosis 
of CSX. The large vessel coronary dysfunction 
(vasospastic angina) presents with angina at rest, 
reversible ischemic ECG changes (usually ST elevation 
rather than depression) and spontaneous/induced 
coronary spasm on angiography. Myocardial bridge is an 
anatomic variant created when the coronary artery 
(typically LAD) tunnels through a segment of 
myocardium [23]. Echocardiogram can be used to rule 
out structural and inflammatory disorders, such as 
hypertrophic cardiomyopathy and pericarditis. Chest 
pain of non-cardiac origin (e.g. gastrointestinal, 
musculoskeletal, pulmonary, or psychiatric) must be 
ruled out. 
The pathogenesis of CSX is considered as the result of 
myocardial ischemia secondary to mircrovascular 
coronary spasm, microvascular stenosis and abnormal 
rheological variables. Chest pain in CSX may be 
hyperawareness of changes in right atrial pressure and 
volume during exertion. Psychologic and behavioral 
factors, such as hypochondriasis, anxiety, and panic 
disorders are common in CSX patients, whose chest 
pain could be usually provoked by stress. Repeated 
episodes of transient ischemia may functionally alter 
cardiac afferent nerve ending to a hypersensitive state 
[7]. Individuals with CSX often show the evidence of 
stress-induced ischemia, most in postmenopausal 
women. 
CSF 
CSF was first described by Tambe et al. in 1972, as 
delayed opacification of coronary vessels during 
angiography without any evident obstructive disease. 
The presentation of CSF is extremely diverse ranging 
from stable or unstable angina, myocardial infarction, to 
ventricular tachycardia. The overall incidence of CSF is 
1% patients who undergo coronary angiography [24, 
25]. 
CSF without established pathogenesis could be affected 
by coronary microvascular stenosis, spasm and blood 
risk factors [24, 26] CSF, sometimes referred to as 
Syndrome Y, is given the proposed role of neuropeptide 
Y. Abnormal constrictor response to neuropeptide Y at 
the mircrocirculation level might be associated with the 
mechanism [27] Microvascular embolization, a result of 
activated platelets and vasoactive debris from plaque 
rupture in epicardial arteries, should play an important 
role in the development of CSF. The clinical features of 
CSF include a higher prevalence in current male 
smokers and rest or mixed-pattern angina rather than 
angina on exertion [2, 24, 25]. 
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MVA 
In 1998, Cannon and Epstein introduced the term of 
MVA for the patients who have chest pain, without fixed 
or dynamic obstruction in epicardial coronary arteries 
on arteriography [2, 5]. MVA can be defined as 
secondary and primary MVA, the latter was classified in 
stable and unstable MVA on the basis of clinical 
presentation [2, 4]. Stable MVA is characterized by 
angina episodes that are exclusively or predominantly 
related to effort and can be identified with the clinical 
entity usually referred as CSX [2]. Unstable primary 
MVA can be defined as a de novo or worsening pattern 
of angina, usually characterized by a prolonged attack or 
recurrent episodes at rest or with mild effort, caused by 
abnormalities in coronary microcirculation. Some of 
these patients also show mild elevation of serum 
markers of myocardial damage, particularly troponins. 
SCF may be a relatively frequent finding in patients with 
unstable MVA. The diagnosis of MVA requires ruling 
out CAD as a cause of the ischemic symptoms. Patients 
with epicardial spasm can be ruled out when their 
presentation is typical (i.e., angina at rest associated with 
ST-segment elevation) or when provocation tests of 
spasm are positive [2] Stress-related cardiomyopathy, 
belonging to unstable MVA, also referred to as apical 
ballooning syndrome or takotsubo disease is usually 
triggered by sudden intense emotional or even physical 
stress. Patients are usually postmenopausal women and 
present with symptoms and signs compatible with acute 
coronary syndrome [2, 4]. 
From the concept and clinical setting, CSX and CSF 
seem to be included in MVA, of which the pathogenesis 
is mainly related with CMD. About half of individuals 
with angina or ischemic heart disease are fail to be 
diagnosed of CAD [6, 28]. The related diseases 
including CSX and CSF due to CMD would be better 
uniformly named as MVA for better communication 
and investigation. Additionally, if the elevations of 
troponins are detectable, coronary microvascular 
myocardial infarction could be diagnosed, given the 
pathophysiology of CMD. The category of 
microvascular myocardial infarction is better than 
subendocardial infarction or non-ST-segment elevation 
myocardial infarction. 
Recently, the following standardized criteria were 
proposed for the investigative diagnosis of MVA due to 
CMD: (1) presence of symptoms suggestive of 
myocardial ischemia; (2) absence of obstructive CAD 
(<50% coronary diameter reduction and/or fractional 
flow reserve (FFR) >0.80); (3) objective evidence of 
myocardial ischemia as well as evidence of impaired 
coronary microvascular function. The latter may be 
documented by (a) an impaired coronary flow reserve 
(CFR) (cut-off values depending on methodology use 
between ≤2.0 and ≤2.5) or (b) coronary microvascular 
spasm, defined as reproduction of symptoms, ischemic 
ECG shifts, but no epicardial spasm during 
acetylcholine testing or (c) abnormal coronary 
microvascular resistance indices (e.g. index of 
microcirculatory resistance, IMR > 25) or (d) CSF, 
defined as TIMI frame count > 25 [6]. 
Assessment of CMD 
Diagnostic indices of CMD could be classified as 
invasive or noninvasive technique. Blood rheological 
variables and biochemical index can be assessed for the 
risk of CMD in the suspected patients with MVA. 
After ruling out the patients with obstructive CAD by 
the conventional angiography, TIMI frame count can 
provide an approximate estimation of epicardial vs. 
microvascular abnormalities [4]. Classically, 
intracoronary acetylcholine has been used as a sensitive 
and safe test for the assessment of coronary vasomotor 
function in the catheterization laboratory. Its 
administration causes vasodilation under normal 
conditions but, in the absence of a functional 
endothelium, it leads to vasoconstriction by the 
unopposed stimulation of muscarinic receptors on 
vascular smooth muscle cells [3, 16]. 
The pressure-temperature sensor-tipped guidewire is 
another effective method of evaluation, allowing 
simultaneous measurement of FFR, CFR and 
calculation of IMR [3, 29]. Coronary blood flow 
measurements at baseline compared with maximal 
hyperemic stimuli are used to evaluate the function of 
the microcirculatory vessels. Adenosine is used as the 
gold standard to invoke an endothelium-independent 
hyperemic response in vessels less than 150μm by 
stimulating the adenosine A2 receptors on smooth 
muscle cells. Same as adenosine, dipyridamole and 
papaverine are also used to trigger arteriolar 
vasodilation, increase coronary blood flow, mainly by a 
direct relaxing effect on vascular smooth muscle cells [3, 
4]. 
IMR showed no correlation with FFR and angiographic 
lesion severity, and the predictors of high IMR value 
were different from those for ischemic FFR value [29] 
Elevated IMR at the time of primary PCI predicts poor 
long-term outcomes [30]. Integration of FFR, CFR and 
IMR investigated the existence of differentiated patterns 
of ischemic heart disease that combine focal and diffuse 
coronary narrowing with variable degrees of CMD [31]. 
Transthoracic echocardiographic Doppler recording of 
coronary blood flow in the left anterior descending 
coronary artery could be used as a first routine method 
to identify CMD. Other non-invasive techniques for 
assessing CMD include the contrast stress 
echocardiography, cardiovascular magnetic resonance, 
and positron emission tomography [2, 3]. 
Treatment of MVA and Blood Healthy 
Therapy 
Systematic reviews of treatment strategies for CMD in 
human subjects with angina, there was little data to 
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support therapies for CMD, and no specific treatment 
was sufficiently well-documented to be recommended 
[32, 33]. Developing strategies for the effective 
treatment of MVA is urgently needed. 
Blood healthy therapy, as a new therapeutic apheresis 
based on isovolumic hemodilution and hemapheresis, 
was previously described [20] Briefly, withdrawing 
some vein blood in a certain ratio of blood/weight, 
separating plasma and blood cells, some plasma or 
erythrocyte would be discarded, if necessary, according 
to consider the rheological variables and blood 
biochemical index. Gradually improved the 
components in blood cells and plasma over a certain 
period of time, the risks factors in blood, such as elevated 
LDL-c, triglyceride, glucose, fibrinogen and large groups 
of macromolecules including inflammatory cytokines, 
could decrease. While discharged some erythrocyte with 
low deformability, the much younger red blood cells 
could carry more oxygen and penetrate into the 
microvasculature. Less erythrocyte aggregates and 
whole blood viscosity decreases. Blood flow velocity 
increases. As all tissue perfusion increased, more oxygen 
and nutrients will be delivered to cells. Spasticity in 
microvascular arteries might relieve. While the blood 
healthy therapy modulates the blood to be thrombosis 
resisting, it will be efficient to decline the rate of acute 
coronary events or stroke [20] and might be effective to 
treat the patients with MVA, including those with high 
hematocrit, increased blood viscosity and CSF, 
especially in the peri- or postmenopausal women. 
CONCLUSIONS 
Researches demonstrate that CMD can lead to 
myocardial ischemia and microvascular myocardial 
infarction. Many patients with chest pain owned to 
CMD. Their prolonged and recurrent chest pain 
necessitates repeated coronary arteriographies and 
regular outpatient visits. The lifetime cost of healthcare 
for this population is often comparable with that caused 
by obstructive CAD. The CMD induced diseases 
including CSX and CSF would be better uniformly 
named as MVA. Blood healthy therapy as a potential 
therapeutic approach in patients with MVA is 
recommended. 
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